Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography

Last updated: June 23, 2020
Sponsor: Bracco Diagnostics, Inc
Overall Status: Terminated

Phase

3

Condition

Heart Disease

Cardiac Disease

Cardiovascular Disease

Treatment

N/A

Clinical Study ID

NCT02282163
BR1-140
  • Ages 9-17
  • All Genders

Study Summary

Safety and Efficacy Study in pediatric subjects aged 9 to 17 years of age with suboptimal LV EBD on non-contrast 2D echocardiography. Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provide Written informed consent from parent(s) or legal guardian

  • Provide assent when required according to local regulations

  • Suspected of having cardiac disease or undergoing evaluation of cardiac anatomy forcongenital heart disease

  • Undergone a previous transthoracic echocardiogram within one month prior to enrollmentresulting in suboptimal left ventricular endocardial border defined as ≥ 2 contiguoussegments in any given view that cannot be visualized.

Exclusion

Exclusion Criteria:

  • Children < 9 years of age

  • Previously enrolled in the study

  • Administered any other contrast agent either intravascularly or orally within 48 hoursof Lumason administration

  • Known right-to-left, bidirectional or transient cardiac shunt (ruled out with agitatedsaline study performed before administration of Lumason)

  • Known hypersensitivity to one or more of the ingredients of the investigationalproduct

  • Received an investigational compound within 30 days before enrolling into this study

  • Pregnant or lactating female

  • Determined by investigator to be unsuitable for the study

Study Design

Total Participants: 13
Study Start date:
October 01, 2015
Estimated Completion Date:
August 31, 2018

Study Description

This was a Phase III, multicenter, open-label study that was to be conducted at approximately 7-12 sites in the United States, Canada and Europe in pediatric patients with suboptimal LV EBD on non-contrast 2D transthoracic echocardiography. It was estimated that 92 patients were to be enrolled to provide 73 evaluable patients.

Three cardiologists unaffiliated with enrolling centers (blinded readers), blinded to the patient's identity and clinical profile were to independently evaluate the echocardiograms. The efficacy analysis was primarily based on the blinded reader evaluations.

Imaging modalities that are used throughout the study in pediatric subjects represented those utilized in routine clinical practice in adults.

One of the sites participating in this study was to be asked to consent a subset of patients for additional blood sampling for analysis of SF6 concentration in blood from a total of 6 patients (3 males and 3 females) in the age group 9 up to 12 years of age and 6 patients (3 males and 3 females) in the age of >12 up to and including 17 years.

The current study was designed to assess the efficacy of Lumason-enhanced echocardiography in pediatric patients.

Connect with a study center

  • Washington University School of Medicine in Saint Louis

    Saint Louis, Missouri 63110
    United States

    Site Not Available

  • University of Nebraska

    Omaha, Nebraska 68114
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.